Evidence map›Paper›PMID 40687235›Full record

ArticleTranslational cancer research2025

Proteomics-based prognostic signature in colon adenocarcinoma patients with familial adenomatous polyposis.

Shi-Qin Li, Wei Jiang, Yu-Cheng Zhu

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shi-Qin Li *Department of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.
Wei Jiang *Department of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.
Yu-Cheng ZhuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Familial adenomatous polyposis (FAP) is regarded as a precancerous stage of colon adenocarcinoma (COAD). COAD concurrent with FAP is quite rare in colorectal cancer screening. In order to create a new COAD prognostic prediction model and to shed light on the landscape of the tumor immune microenvironment in COAD, we examined differentially expressed genes (DEGs) between COAD and FAP in this study. Methods: DEGs between COAD and FAP were identified using proteomic technology. Expression matrix data for COAD were obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Using multivariate and least absolute shrinkage and selection operator (LASSO) regression analyses, a prognostic risk model for COAD concurrent with FAP (COAD-FAP) was created. In the training and validation sets, the efficacy of the risk model was confirmed, respectively. A systematic analysis was conducted on the relationships between the prognostic signature and immunological score, tumor immune cell infiltration, and immune checkpoints. Results: A survival risk model was constructed using four prognostic genes: fatty acid-binding protein 4 ( Conclusions: These findings imply that the four COAD-FAP risk signatures could be a practical tool for forecasting prognostic risk, assessing immunotherapy efficacy, and personalizing customized treatment choices for COAD patients.

Indexed as

Colon adenocarcinoma (COAD)familial adenomatous polyposis (FAP)immune infiltrationprognosisrisk stratification

Identifiers

PMID40687235
PMCPMC12268895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.